AVEO Pharmaceuticals (AVEO) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to AVEO Pharmaceuticals (AVEO) Misses Q3 EPS by 6c
March 9, 2015 6:50 AM EDT
(Updated - March 9, 2015 8:05 AM EDT)
RBC Capital upgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Underperform to Sector Perform with a price target of $3.00 (from $2.00). Analyst Adnan Butt thinks shares could begin reflecting pipeline optionality.
"Since the setback with tivozanib in renal cancer,... More
March 6, 2015 7:09 AM EST
AVEO Oncology (NASDAQ: AVEO) announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). The presentation, titled Neuropilin-1 as a potential biomarker of progression-free survival benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC Phase 2 trial, will be presented in a poster session today at the American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization... More
March 5, 2015 12:32 PM EST
As AVEO Pharmaceuticals (NASDAQ: AVEO) traders pare some gains, more might be in the works amid recent trading data.
The 14-day money flow index in AVEO is at 93 percent, indicating that the stock was vastly overbought. The last time shares... More
